Xlife Sciences AG (FRA:XLS) Loans Receivable: €0.00 Mil (As of Dec. 2025)


FRA:XLS Xlife Sciences AG FRA:XLS
47 GF Score
Price €19.20
GF Value €7.64
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Loans Receivable?

Xlife Sciences AG FRA:XLS -2.54% 47 Loans Receivable is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:XLS with a GF Score™ of 47/100 and a GF Value™ of €7.64 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Xlife Sciences AG's Loans Receivable for the quarter that ended in Dec. 2025 was €0.00 Mil.

Xlife Sciences AG Loans Receivable Related Terms

Xlife Sciences AG Loans Receivable Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Loans Receivable Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Loans Receivable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:XLS
47GF Score
Xlife Sciences AG FRA:XLS
Loans Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.

Frequently Asked Questions Learn more about Loans Receivable →
What does a Loans Receivable of €0.00 Mil mean?
Xlife Sciences AG (FRA:XLS) has a Loans Receivable of €0.00 Mil as of Dec. 2025. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Loans Receivable too high?
Xlife Sciences AG's current Loans Receivable is €0.00 Mil. Overall, Xlife Sciences AG has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Loans Receivable compare to VRTX and REGN?
Xlife Sciences AG's Loans Receivable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Loans Receivable for a Biotechnology company?
A good Loans Receivable depends on the Biotechnology industry context. However, Loans Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Loans Receivable mean?
A high Loans Receivable can signal that a stock is expensive relative to its fundamentals. Loans Receivable are the funds that a company has lent but have not yet been repaid. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Loans Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (FRA:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.64, compared to a current price of €19.20 — trading 151.3% above its estimated fair value. The current Loans Receivable is €0.00 Mil. Xlife Sciences AG's overall GF Score™ is 47/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Loans Receivable calculated?
Loans Receivable is calculated from a company's financial statements. For Xlife Sciences AG (FRA:XLS), the current Loans Receivable is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (FRA:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of €19.20 is trading 151.3% above its estimated GF Value™ of €7.64. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for FRA:XLS:

  • Loans Receivable: €0.00 Mil
  • GF Value™: €7.64 vs. price of €19.20 (151.3% above fair value)
  • GF Score™: 47/100 with 10 warning signs

No single metric tells the full story. See the FRA:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Switzerland
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
47GF Score

Get the complete analysis for FRA:XLS

Loans Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.20
Price
€7.64
GF Value